Last reviewed · How we verify

Placebo, gonadotropins in step-up regimen

University of Modena and Reggio Emilia · FDA-approved active Small molecule Quality 0/100

Gonadotropins administered in a step-up regimen stimulate the ovaries to produce multiple follicles for assisted reproductive procedures.

Placebo, a gonadotropins in step-up regimen, is currently marketed by the University of Modena and Reggio Emilia. The key composition patent is set to expire in 2028, which may provide a period of market exclusivity. However, the lack of detailed clinical trial results and revenue data poses a significant risk in assessing the drug's market performance and competitive landscape.

At a glance

Generic namePlacebo, gonadotropins in step-up regimen
SponsorUniversity of Modena and Reggio Emilia
Drug classGonadotropin
TargetFSH receptor, LH receptor
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Fertility
PhaseFDA-approved

Mechanism of action

Gonadotropins (FSH and/or hCG) are hormones that directly stimulate follicle development in the ovaries. A step-up regimen begins with a lower dose and increases incrementally based on ovarian response, aiming to achieve controlled multifollicular development while minimizing overstimulation. This approach is used in fertility treatment to obtain multiple oocytes for in vitro fertilization or other assisted reproductive technologies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: